Drug Type Small molecule drug |
Synonyms Azimilide, Stedicor, 阿齐利特 + [1] |
Target |
Action blockers |
Mechanism Potassium channel blockers |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedNDA/BLA |
First Approval Date- |
Regulation- |
Molecular FormulaC23H30Cl3N5O3 |
InChIKeyHHPSICLSNHCSNZ-UHFFFAOYSA-N |
CAS Registry149888-94-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Azimilide Hydrochloride | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atrial Fibrillation | NDA/BLA | United States | - | |
Atrial Flutter | NDA/BLA | United States | - | |
Arrhythmias, Cardiac | Phase 3 | United States | 01 Nov 2011 | |
Arrhythmias, Cardiac | Phase 3 | Belgium | 01 Nov 2011 | |
Arrhythmias, Cardiac | Phase 3 | Canada | 01 Nov 2011 | |
Arrhythmias, Cardiac | Phase 3 | Czechia | 01 Nov 2011 | |
Arrhythmias, Cardiac | Phase 3 | Denmark | 01 Nov 2011 | |
Arrhythmias, Cardiac | Phase 3 | France | 01 Nov 2011 | |
Arrhythmias, Cardiac | Phase 3 | Germany | 01 Nov 2011 | |
Arrhythmias, Cardiac | Phase 3 | Israel | 01 Nov 2011 |
Not Applicable | - | 240 | hwgcxytbjz(dhpmtoacqu): OR = 0.79 (95% CI, 0.44 - 1.44) View more | Negative | 01 Mar 2017 | ||
Placebo |